Synonyms: OPC-167832
Compound class:
Synthetic organic
Comment: Quabodepistat is a 3,4-dihydrocarbostyril derivative. It is an inhibitor of decaprenylphosphoryl-beta-D-ribose oxidase (DprE1), an essential mycobacterial cell wall biosynthesis enzyme, and has potent antimycobacterial activity [3]. Quabodepistat is under clinical development by Otsuka Pharmaceutical (Tokyo, Japan) as a treatment for tuberculosis (TB).
|
|
No information available. |
Summary of Clinical Use |
Quabodepistat is under clinical evaluation as an oral treatment for TB. In a first-in-human study (NCT03678688), the drug demonstrated favorable pharmacokinetic, tolerability and safety profiles, while exhibiting high early bactericidal activity in participants with drug-susceptible tuberculosis (DS-TB) [1]. A Phase 2 study to evaluate the safety and efficacy of quabodepistat combined with delamanid and bedaquiline in participants with DS-TB (NCT05221502) is due to complete in April 2024 [2]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05971602 | Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis | Phase 2 Interventional | Bill & Melinda Gates Medical Research Institute | ||
NCT05221502 | Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB | Phase 2 Interventional | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | |
NCT03678688 | A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis | Phase 1/Phase 2 Interventional | Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 |